Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, D'Onofrio F
Department of Gerontology and Metabolic Diseases, Second University of Naples, Italy.
Diabetes Care. 1993 Oct;16(10):1387-90. doi: 10.2337/diacare.16.10.1387.
To determine the effects of metformin on blood pressure, left ventricular mass, and some metabolic and endocrine parameters in nondiabetic, obese, hypertensive women.
Twelve obese, nondiabetic, hypertensive women received 850 mg metformin 2 times/day for 12 wk and placebo for another 12 wk, according to a double-blind, cross-over, randomized design. All patients were hospitalized 4 times, i.e., before randomization and after each treatment (metformin or placebo), to conduct metabolic and cardiovascular investigations (oral glucose tolerance test, euglycemic clamp associated with indirect calorimetry, and echocardiography).
Fasting glucose, HbA1c, fasting and glucose-stimulated insulin, blood pressure and left ventricular mass, cholesterol, triglycerides, and fibrinogen decreased significantly after metformin treatment, whereas high-density lipoprotein cholesterol increased. The improvement in glucose metabolism resulted from increased sensitivity to insulin.
These findings suggest that metformin treatment in obese, nondiabetic, hypertensive women produces a more favorable cardiovascular risk profile.
确定二甲双胍对非糖尿病、肥胖、高血压女性的血压、左心室质量以及一些代谢和内分泌参数的影响。
根据双盲、交叉、随机设计，12名肥胖、非糖尿病、高血压女性每天服用2次850毫克二甲双胍，持续12周，然后服用安慰剂12周。所有患者均住院4次，即随机分组前以及每次治疗（二甲双胍或安慰剂）后，进行代谢和心血管检查（口服葡萄糖耐量试验、与间接量热法相关的正常血糖钳夹试验以及超声心动图检查）。
二甲双胍治疗后，空腹血糖、糖化血红蛋白、空腹及葡萄糖刺激的胰岛素、血压和左心室质量、胆固醇、甘油三酯和纤维蛋白原显著降低，而高密度脂蛋白胆固醇升高。葡萄糖代谢的改善源于对胰岛素敏感性的增加。
这些发现表明，二甲双胍治疗肥胖、非糖尿病、高血压女性可产生更有利的心血管风险状况。
